Cannabis treatment for teenage patients with autism is well-tolerated, safe and effective option to relieve symptoms including seizures, tics, depression, restlessness, researchers say.
The study found that after six months of treatment, 30 per cent of patients reported a significant improvement, 53.7 per cent reported moderate improvement and only 15 per cent had slight or no change.
"Overall, more than 80 per cent of the parents reported significant or moderate improvement in their child," said co-author Lihi Bar-Lev Schleider from the Ben-Gurion University of the Negev in Israel.
Autistic Spectrum Disorder (ASD) is an extensive developmental disorder that is expressed in almost all dimensions of the child's development.
It is now common to refer to this disorder as a wide range of Pervasive Developmental Disorders (PDD) in which there are various manifestations and symptoms.
For the study, published in the journal Scientific Reports, the team analysed the data prospectively collected as part of the treatment programme of 188 ASD patients treated with medical cannabis between 2015 and 2017.
The treatment in majority of the patients was based on cannabis oil containing 30 per cent cannabidiol oil (CBD) and 1.5 per cent tetrahydrocannabinol (THC).
Good quality of life was reported by 31.3 per cent of patients prior to treatment initiation. At six months, good quality of life more than doubled for 66.8 per cent.
Positive mood was reported by 42 per cent before treatment and 63.5 after six months.
"While this study suggest that cannabis treatment is safe and can improve ASD symptoms and improve ASD patients' quality of life, we believe that double blind placebo-controlled trials are crucial for a better understanding..." said co-author Victor Novack from the varsity.
The Council of Scientific and Industrial Research (CSIR) is doing a research on the medicinal use of cannabis for treating diseases like cancer, epilepsy and sickle cell anaemia.
In the US, medical marijuana is legal in 30 states, though the laws governing what is permitted vary from state to state, according to the National Conference of State Legislatures.
--IANS
vc/oeb/in
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
